Browse Category

Merck News 30 November 2025 - 19 December 2025

Merck (MRK) Stock After Hours: Key News, Analyst Calls, and What to Watch Before the Dec. 19, 2025 Market Open

Merck & Co., Inc. (NYSE: MRK) ended Thursday, December 18, 2025, on a strong note—and then barely budged after the closing bell—after a day that mixed a bullish analyst upgrade with a fresh round of healthcare-policy headlines and pipeline developments

19 December 2025

Merck (MRK) Stock After Hours Today (Dec. 15, 2025): What’s Moving Shares and What to Watch Before Tuesday’s Open

Merck & Co., Inc. (NYSE: MRK) — known as MSD outside the U.S. and Canada — is ending Monday’s session (December 15, 2025) with investors focused on a mix of “quiet tape” trading, fresh analyst commentary, and a key shareholder

16 December 2025

After Hours Trading · Financial News · Investing · Merck · NYSE:MRK · Stock Market

Merck (MRK) Stock After Hours on December 10, 2025: What to Watch Before the December 11 Open

Merck & Co., Inc. (NYSE: MRK) heads into the December 11, 2025 U.S. trading session with its share price stabilizing after a volatile stretch driven by earnings, pipeline news, and a major flu-drug acquisition. Here’s a structured look at what

11 December 2025

After Hours Trading · Financial News · Investment Tips · Merck · NYSE:MRK · Stock Market

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the

10 December 2025

After-Hours Trading · Keytruda · Merck · NYSE:MRK · Pharmaceuticals · Stock Market

Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck & Co. (NYSE: MRK) is ending November 2025 on a strong note. A flurry of regulatory wins for cancer drug Keytruda, positive mid‑stage data for heart drug Winrevair, and fresh deal‑making have pushed the share price close to its

30 November 2025

Analyst Forecasts · Financial News · Investment · Merck · NYSE:MRK · Stock Market

Go toTop